PharmaCross SRL
PharmaCross reported revenue of €18.2m for the 2025 financial year (annual accounts filed with the NBB on 11 Aug 2026).
The score of PharmaCross shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue -1 % Equity -75 % Total assets -54 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
PharmaCross's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €18.2m | ||||
| Net result | 503,893 € | ||||
| Equity | €1.23m | ||||
| Cash | 455,154 € | ||||
| EBITDA | 445,471 € | ||||
| Total assets | €3.28m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 11 Aug 2026
- Year ended 31 Dec 2024filed on 15 Jul 2025
- Year ended 31 Dec 2023filed on 02 Jul 2024
- Year ended 31 Dec 2022filed on 14 Jul 2023
- Year ended 31 Dec 2021filed on 13 Jul 2022
PharmaCross's financial analysis
- Solvency37.6%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of PharmaCross
PharmaCross's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0888.580.475
- VAT number
- BE0888580475
- Peppol
- Registered · 0208:0888580475 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 05 Apr 2007
- Registered office
- 9850 Deinze
- Latest accounts
- 2025 · filed on 11 Aug 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
PharmaCross (SRL) has been based in Deinze since 2007, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports revenue of €18.2m, a net profit of 503,893 € and equity of €1.23m. Its solvency stands at 37.6%, below the median of its sector (46.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to PharmaCross
Companies in the same business, of comparable size and area, outside its group.
- Orifarm Belgium Wholesale of pharmaceutical and medical goods Ghent · balance sheet €5.00m
- Endoceutics Wholesale of pharmaceutical and medical goods Brussels · balance sheet €3.45m
- Launchpad Europe Wholesale of pharmaceutical and medical goods Oostkamp · balance sheet 120,635 €
- Maimonides Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 142 €
- Biocon Biologics Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €1.09m
- Wimeq Wholesale of pharmaceutical and medical goods Heusden-Zolder · balance sheet 48,978 €
- MiniMed Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet 8,076 €
- Axon Lab Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €3.28m
Frequently asked questions about PharmaCross
What is the revenue of PharmaCross?
According to the 2025 annual accounts filed with the NBB, the revenue of PharmaCross amounts to 18,186,018 €.
What is the VAT number of PharmaCross?
In Belgium, the VAT number is the company number prefixed with BE: BE0888580475 for PharmaCross, if the company is VAT-registered. Its company number (CBE) is 0888.580.475.
Where is the registered office of PharmaCross?
According to the CBE register, the registered office of PharmaCross is in 9850 Deinze.
What is the equity of PharmaCross?
At the close of the 2025 financial year, the equity of PharmaCross amounts to 1,231,195 €, a solvency of 37.6% of total assets.
Who manages PharmaCross?
The register lists 1 active mandates at PharmaCross. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of PharmaCross
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →